$MBRX
Moleculin Biotech, Inc.

2019 Q2 Form 10-Q Financial Statement

#000165961719000069 Filed on May 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.480M $1.590M $1.390M
YoY Change 21.31% 14.39% 63.53%
% of Gross Profit
Research & Development $2.099M $2.932M $1.237M
YoY Change -50.39% 137.03% 81.11%
% of Gross Profit
Depreciation & Amortization $49.00K $48.00K $8.000K
YoY Change 600.0% 500.0% 100.0%
% of Gross Profit
Operating Expenses $3.632M $4.571M $2.637M
YoY Change -33.46% 73.34% 71.79%
Operating Profit -$3.632M -$4.571M -$2.637M
YoY Change -33.46% 73.34% 71.79%
Interest Expense $2.410M $530.0K $710.0K
YoY Change 630.3% -25.35% 70900.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change -100.0%
Pretax Income -$1.220M -$4.040M -$1.930M
YoY Change -76.22% 109.33% 484.85%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.221M -$4.041M -$1.927M
YoY Change -76.18% 109.7% 485.71%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$172.6K -$834.7K -$496.1K
COMMON SHARES
Basic Shares Outstanding 45.19M shares 28.53M shares 25.77M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.70M $8.780M $13.11M
YoY Change 59.56% -33.03% 47.64%
Cash & Equivalents $18.70M $8.782M $13.11M
Short-Term Investments
Other Short-Term Assets $1.510M $830.0K $630.0K
YoY Change 29.06% 31.75% 133.33%
Inventory
Prepaid Expenses $1.507M $831.0K
Receivables
Other Receivables
Total Short-Term Assets $20.20M $9.613M $13.75M
YoY Change 56.7% -30.08% 50.25%
LONG-TERM ASSETS
Property, Plant & Equipment $401.0K $431.0K $33.00K
YoY Change 1442.31% 1206.06% 65.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.65M $11.69M $11.18M
YoY Change 4.28% 4.51% 0.13%
TOTAL ASSETS
Total Short-Term Assets $20.20M $9.613M $13.75M
Total Long-Term Assets $11.65M $11.69M $11.18M
Total Assets $31.85M $21.30M $24.93M
YoY Change 32.36% -14.57% 22.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.257M $2.799M $570.0K
YoY Change -25.0% 391.05% -33.72%
Accrued Expenses $1.390M $1.251M $766.0K
YoY Change -24.42% 63.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.591M $6.436M $1.799M
YoY Change 133.02% 257.75% -18.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $170.0K $180.0K $2.560M
YoY Change -94.69% -92.97% 29.95%
Total Long-Term Liabilities $170.0K $180.0K $2.560M
YoY Change -94.69% -92.97% 29.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.591M $6.436M $1.799M
Total Long-Term Liabilities $170.0K $180.0K $2.560M
Total Liabilities $9.762M $6.616M $4.359M
YoY Change 33.4% 51.78% 4.28%
SHAREHOLDERS EQUITY
Retained Earnings -$31.60M -$30.40M -$16.41M
YoY Change 46.98% 85.29%
Common Stock $53.69M $45.06M $36.98M
YoY Change 40.27% 21.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.09M $14.68M $20.57M
YoY Change
Total Liabilities & Shareholders Equity $31.85M $21.30M $24.93M
YoY Change 32.36% -14.57% 22.68%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$1.221M -$4.041M -$1.927M
YoY Change -76.18% 109.7% 485.71%
Depreciation, Depletion And Amortization $49.00K $48.00K $8.000K
YoY Change 600.0% 500.0% 100.0%
Cash From Operating Activities -$5.340M -$3.847M -$2.807M
YoY Change 54.34% 37.05% 101.8%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $15.00K $8.000K
YoY Change 87.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$15.00K -$8.000K
YoY Change 87.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.516M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.28M $5.521M $8.215M
YoY Change 641.75% -32.79% 56.03%
NET CHANGE
Cash From Operating Activities -5.340M -$3.847M -$2.807M
Cash From Investing Activities -10.00K -$15.00K -$8.000K
Cash From Financing Activities 15.28M $5.521M $8.215M
Net Change In Cash 9.930M $1.648M $5.400M
YoY Change -809.29% -69.48% 39.39%
FREE CASH FLOW
Cash From Operating Activities -$5.340M -$3.847M -$2.807M
Capital Expenditures -$10.00K $15.00K $8.000K
Free Cash Flow -$5.330M -$3.862M -$2.815M
YoY Change 54.05% 37.19% 102.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
Moleculin Biotech, Inc.
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Trading Symbol
TradingSymbol
MBRX
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45192048 shares
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001659617
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28528663 shares
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34409030 shares
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34409030 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28528663 shares
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
809000 USD
CY2017Q3 mbx Classof Warrantor Right Agreement Period
ClassofWarrantorRightAgreementPeriod
P12M
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2016Q2 mbx Shares Authorized
SharesAuthorized
80000000 shares
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016Q2 mbx Licensing Agreement Term
LicensingAgreementTerm
P3Y
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45192048 shares
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8782000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7134000 USD
CY2019Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
831000 USD
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
840000 USD
CY2019Q1 us-gaap Assets Current
AssetsCurrent
9613000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
7974000 USD
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
431000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
463000 USD
CY2019Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2018Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
106000 USD
CY2019Q1 us-gaap Assets
Assets
21298000 USD
CY2018Q4 us-gaap Assets
Assets
19585000 USD
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2799000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1246000 USD
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1251000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2452000 USD
CY2019Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2386000 USD
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
180000 USD
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6436000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3878000 USD
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
180000 USD
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
107000 USD
CY2019Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2018Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1328000 USD
CY2019Q1 us-gaap Liabilities
Liabilities
6616000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
5313000 USD
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
34000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
29000 USD
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
45021000 USD
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
40564000 USD
CY2019Q1 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
24000 USD
CY2018Q4 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
35000 USD
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30397000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-26356000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
14682000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
14272000 USD
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21298000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19585000 USD
CY2019Q1 us-gaap Revenues
Revenues
0 USD
CY2018Q1 us-gaap Revenues
Revenues
0 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2932000 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1237000 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1591000 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1392000 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
48000 USD
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8000 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
4571000 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2637000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4571000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2637000 USD
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-529000 USD
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-709000 USD
CY2019Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1000 USD
CY2018Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4041000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1927000 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29064913 shares
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23331685 shares
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4041000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1927000 USD
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-11000 USD
CY2018Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4052000 USD
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1927000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4041000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1927000 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
48000 USD
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
348000 USD
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
242000 USD
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-529000 USD
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-709000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-9000 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
46000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1553000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-239000 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1235000 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-136000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3847000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2807000 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000 USD
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000 USD
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000 USD
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2019Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2018Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
15000 USD
CY2019Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5516000 USD
CY2018Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
8200000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5521000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8215000 USD
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-11000 USD
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1648000 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5400000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7134000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7714000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8782000 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13114000 USD
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
1000 USD
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
1000 USD
CY2019Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000 USD
CY2018Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5000 USD
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
106000 USD
CY2019Q1 mbx Recognition Of Operating Lease Liabilities
RecognitionOfOperatingLeaseLiabilities
213000 USD
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
41000 USD
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
14272000 USD
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3226000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
348000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4041000 USD
CY2019Q1 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-11000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
14682000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
17118000 USD
CY2018Q1 mbx Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
15000 USD
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5122000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
242000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1927000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
20570000 USD
CY2019Q1 mbx Number Of Drug Technologies
NumberOfDrugTechnologies
3 technology
CY2019Q1 mbx Numberof Drug Candidates
NumberofDrugCandidates
6 candidate
CY2019Q1 mbx Numberof Drugsin Clinical Trials
NumberofDrugsinClinicalTrials
3 drug
CY2019Q1 mbx Numberof Clinical Trials
NumberofClinicalTrials
4 clinicalTrial
CY2019Q1 mbx Number Of Other Drug Development Projects
NumberOfOtherDrugDevelopmentProjects
5 project
CY2019Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates - The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30400000 USD
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
140000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
93000 USD
CY2019Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Reclassifications - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">A reclassification was made to the prior period financial statements to conform to the 2019 presentation. Such reclassification did not affect net loss as previously reported. Historically, "Deferred compensation - related party" was a separate line item on the balance sheet. Management believes that this balance is best shown included in "accrued expenses and other current liabilities," and, as such, a reclassification was made to the balance sheet for the period ended December 31, 2018 to include "deferred compensation - related party" in with "accrued liabilities and other current liabilities."</span>
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9546015 shares
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4516524 shares
CY2019Q1 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
639000 USD
CY2018Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
492000 USD
CY2019Q1 mbx Accrued Clinical Testing Current
AccruedClinicalTestingCurrent
230000 USD
CY2018Q4 mbx Accrued Clinical Testing Current
AccruedClinicalTestingCurrent
95000 USD
CY2019Q1 mbx Accrued License Fees And Sra Current
AccruedLicenseFeesAndSRACurrent
196000 USD
CY2018Q4 mbx Accrued License Fees And Sra Current
AccruedLicenseFeesAndSRACurrent
1147000 USD
CY2019Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
103000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
91000 USD
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
33000 USD
CY2019Q1 mbx Accrued Drug Manufacturing Cost
AccruedDrugManufacturingCost
1000 USD
CY2018Q4 mbx Accrued Drug Manufacturing Cost
AccruedDrugManufacturingCost
400000 USD
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
49000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
227000 USD
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1251000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2452000 USD
CY2019Q1 mbx Shares Authorized
SharesAuthorized
80000000 shares
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 mbx Sale Of Stock Maximum Amount Of Common Stock To Be Sold In Transaction
SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction
20000000.0 USD
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2794000 shares
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.78
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.61
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y5M4D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21200 USD
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2019Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25000 shares
CY2019Q1 mbx Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
0.13
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.20
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2769000 shares
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.81
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.65
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M26D
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
535833 shares
CY2019Q1 mbx Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
2.58
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.35
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M28D
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
348000 USD
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
242000 USD
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2900000 USD
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M18D
CY2018Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2300000 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
10000.00 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
55000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
10000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
266000 USD
CY2019Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
10000.00 USD
CY2019Q1 us-gaap Variable Lease Cost
VariableLeaseCost
5000.000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
39000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
53000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
54000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
55000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
53000 USD
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
213000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
48000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
53000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
54000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
55000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
56000 USD
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M24D
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2016Q2 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
750000 USD
CY2016Q2 mbx Payments For Research And Development Agreement
PaymentsForResearchAndDevelopmentAgreement
1000000.0 USD
CY2018Q2 mbx Payments For Research And Development Agreement
PaymentsForResearchAndDevelopmentAgreement
1000000.0 USD
CY2019Q1 mbx Employee Agreements Special Termination Benefits Numberof Employees
EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees
9 employee
CY2019Q1 mbx Employee Agreements Termination Benefits Provided To Key Employees Aggregate Amount
EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount
1200000 USD

Files In Submission

Name View Source Status
0001659617-19-000069-index-headers.html Edgar Link pending
0001659617-19-000069-index.html Edgar Link pending
0001659617-19-000069.txt Edgar Link pending
0001659617-19-000069-xbrl.zip Edgar Link pending
a2019q1ex311-xnextgen.htm Edgar Link pending
a2019q1ex312-xnextgen.htm Edgar Link pending
a2019q1ex321-xnextgen.htm Edgar Link pending
a2019q1ex322-xnextgen.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mbx-20190331.htm Edgar Link pending
mbx-20190331.xsd Edgar Link pending
mbx-20190331_cal.xml Edgar Link unprocessable
mbx-20190331_def.xml Edgar Link unprocessable
mbx-20190331_g1.jpg Edgar Link pending
mbx-20190331_htm.xml Edgar Link completed
mbx-20190331_lab.xml Edgar Link unprocessable
mbx-20190331_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending